Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [ <scp> <sup>177</sup> Lu </scp> ]Lu‐ <scp>DOTA</scp> ‐ <scp>TATE</scp> : Ad Hoc Analy
These results suggest the benefit of PRRT and the potential PFS and OS benefit of <sup>177</sup>Lu-DOTATATE should not be based on tumor shrinkage (objective response versus stable disease) and that lack of tumor shrinkage should not impact application of the approved four cycles of <sup>177</sup>Lu-DOTATATE.
Authors
- Philippe Ruszniewski
- Martyn Caplin (ORCID: https://orcid.org/0000-0003-0177-1352)
- Marianne Pavel (ORCID: https://orcid.org/0000-0002-9669-5294)
- Marianna Hertelendi (ORCID: https://orcid.org/0000-0001-9819-7902)
- Jonathan Strosberg (ORCID: https://orcid.org/0000-0001-8405-218X)
- Eric P. Krenning (ORCID: https://orcid.org/0009-0001-0190-1180)
Institutions
- Novartis (Switzerland) (CH)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Université Paris Cité (FR)
- University of South Florida (US)
- Hôpital Beaujon (FR)
- The Royal Free Hospital (GB)
- Moffitt Cancer Center (US)
- Cyclotron (Netherlands) (NL)
- Comprehensive Cancer Center Erlangen (DE)
- University College London (GB)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1002/cam4.70744
- Citations
- 4
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 5.42
Funders
- Advanced Accelerator Applications